Nuvectis Licenses Two Clinical-Stage Compounds, NXP100 Shows Superiority to Soliris in Phase 3 PNH Trial
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (3.7× avg).
Summary
Nuvectis Pharma secured exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, from Haisco Pharmaceutical Group. NXP100, a Factor B inhibitor, demonstrated superiority to Soliris in a Phase 3 study for Paroxysmal Nocturnal Hemoglobinuria (PNH), with two MAAs already submitted in China. This significantly expands Nuvectis' pipeline with potentially best-in-class assets, adding a late-stage program with strong clinical validation. The deal follows Nuvectis' Q1 report of a net loss and cash burn, making this pipeline expansion critical for future growth. The company is hosting a conference call today at 8:30 AM ET to discuss the new products.
At the time of this announcement, NVCT was trading at $14.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $366.6M. The 52-week trading range was $5.55 to $14.16. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.